The tachykinin NK1 receptor in the brain: Pharmacology and putative functions

European Journal of Pharmacology

Volumn 375, Issue 1-3, 1999, Pages 51-60

  Saria, Alois ^a  

^a UNIVERSITY HOSPITAL INNSBRUCK   (Austria)

Author keywords

Anxiety; Basal ganglia; Brain; Depression; Emesis; Neurokinin; Non peptidic antagonist; Tachykinin; Tachykinin NK1 receptor

Indexed keywords

2 BENZHYDRYL 3 (2 METHOXYBENZYLAMINO) 1 AZABICYCLO[2.2.2]OCTANE; 2 [1 IMINO 2 (2 METHOXYPHENYL)ETHYL] 7,7 DIPHENYLPERHYDROISOINDOL 4 ONE; 3 (2 METHOXYBENZYLAMINO) 2 PHENYLPIPERIDINE; ANTIDEPRESSANT AGENT; DOPAMINE 2 RECEPTOR BLOCKING AGENT; GRANISETRON; IMIPRAMINE; NEUROKININ 1 RECEPTOR; NEUROKININ 1 RECEPTOR AGONIST; NEUROKININ 1 RECEPTOR ANTAGONIST; NEUROLEPTIC AGENT; PAROXETINE; TACHYKININ RECEPTOR; TACHYKININ RECEPTOR AGONIST;

BASAL GANGLION; BRAIN; DEPRESSION; DRUG RECEPTOR BINDING; MAMMAL; NOCICEPTION; NONHUMAN; PRIORITY JOURNAL; REVIEW; SPINAL CORD; VOMITING; ANIMAL; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; DRUG ANTAGONISM; DRUG EFFECT; HUMAN; PHYSIOLOGY; SPECIES DIFFERENCE;

ANIMALS; BASAL GANGLIA; BRAIN; CLINICAL TRIALS; DEPRESSION; HUMANS; RECEPTORS, NEUROKININ-1; SPECIES SPECIFICITY; SPINAL CORD; VOMITING;

EID: 0032587925     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(99)00259-9     Document Type: Review

References (115)

1. 2 receptor antagonist raclopride: correlation with extracellular acetylcholine levels in striatum. J. Pharmacol. Exp. Ther. 274:1995;928-936.
2. 1 receptor expression by cholinergic interneurones in human striatum. NeuroReport. 5:1994;1597-1600.
3. Bannon M.J., Whitty C.J. Neurokinin receptor gene expression in substantia nigra: localization, regulation, and potential physiological significance. Can. J. Physiol. Pharmacol. 73:1995;866-870.
4. Bannon M.J., Lee J.M., Giraud P., Young A., Affolter H.U., Bonner T.I. Dopamine antagonist haloperidol decreases substance P, substance K, and preprotachykinin mRNA. J. Biol. Chem. 261:1986;6640-6642.
5. Bannon M.J., Elliott P.J., Bunney E.B. Striatal tachykinin biosynthesis: regulation of mRNA and peptide levels by dopamine agonists and antagonists. Brain Res. 427:1987;31-37.
6. Barker R. Substance P and Parkinson's disease: a causal relationship? J. Theor. Biol. 120:1986;353-362.
7. Barker R. Model for basal ganglia disorders. TINS. 13:1990;93-93.
8. Barker R. Substance-P and neurodegenerative disorders - a speculative review. Neuropeptides. 20:1991;73-78.
9. Barker R. Tachykinins, neurotrophism and neurodegenerative diseases: a critical review on the possible role of tachykinins in the aetiology of CNS diseases. Rev. Neurosci. 7:1996;187-214.
10. 125I ]Bolton Hunter derivatives of eledoisin and substance P in the rat brain Neuroscience. 18:1986;857-875.
11. 2 tachykinin receptor antagonists, CP-99,994 and SR 48968, in the guinea-pig and cat. Br. J. Pharmacol. 121:1997;165-170.
12. 1 receptor antagonist, CP-99,994, in ferrets. Eur. J. Pharmacol. 249:1993;R3-R4.
13. 1 receptor activation in gerbils. Eur. J. Pharmacol. 253:1994;245-252.
14. 1 receptor antagonist affects the circadian regulation of locomotor activity in golden hamsters. Brain Res. 800:1998;32-39.
15. Culman J., Klee S., Ohlendorf C., Unger T. Effect of tachykinin receptor inhibition in the brain on cardiovascular and behavioral responses to stress. J. Pharmacol. Exp. Ther. 280:1997;238-246.
16. Dam T.V., Quirion R. Pharmacological characterization and autoradiographic localization of substance P receptors in guinea pig brain. Peptides. 7:1986;855-864.
17. Danks J.A., Rothman R.B., Cascieri M.A., Chicchi G.G., Liang T., Herkenham M. A comparative autoradiographic study of the distributions of substance P and eledoisin binding sites in rat brain. Brain Res. 385:1986;273-281.
18. De F.C., Herrero J.F., O'Brien J.A., Palmer J.A., Doyle C.A., Smith A.J., Laird J.M., Belmonte C., Cervero F., Hunt S.P. Altered nociception, analgesia and aggression in mice lacking the receptor for substance P. Nature. 392:1998;394-397. see comments.
19. Elliott P.J., Iversen S.D. Behavioural effects of tachykinins and related peptides. Brain Res. 381:1986;68-76.
20. Elliott P.J., Mason G.S., Graham E.A., Turpin M.P., Hagan R.M. Modulation of the rat mesolimbic dopamine pathway by neurokinins. Behav. Brain Res. 51:1992;77-82.
21. File S.E. Anxiolytic action of a neurokinin1 receptor antagonist in the social interaction test. Pharmacol. Biochem. Behav. 58:1997;747-752.
22. Fong T.M., Yu H., Strader C.D. Molecular basis for the species selectivity of the neurokinin-1 receptor antagonist CP-96345. J. Biol. Chem. 267:1992;25668-25671.
23. Futami T., Hatanaka Y., Matsushita K., Furuya S. Expression of substance P receptor in the substantia nigra. Brain Res. Mol. Brain Res. 54:1998;183-198.
24. Garcia M., Sakamoto K., Shigekawa M., Nakanishi S., Ito S. Multiple mechanisms of arachidonic acid release in Chinese hamster ovary cells transfected with cDNA of substance P receptor. Biochem. Pharmacol. 48:1994;1735-1741.
25. Garret C., Carruette A., Fardin V., Moussaoui S., Peyronel J.F., Blanchard J.C., Laduron P.M. Pharmacological properties of a potent and selective nonpeptide substance P antagonist. Proc. Natl. Acad. Sci. USA. 88:1991;10208-10212.
26. Goldstein D.J., Wang O., Saper J.R., Stoltz R., Silberstein S.D., Mathew N.T. Ineffectiveness of neurokinin-1 antagonist in acute migraine: a crossover study. Cephalalgia. 17:1997;785-790.
27. 1 receptor antagonist, in ferrets. Eur. J. Pharmacol. 305:1996;181-185.
28. Gorbulev V., Akhundova A., Luzius H., Fahrenholz F. Molecular cloning of substance P receptor cDNA from guinea-pig uterus. Biochim. Biophys. Acta. 1131:1992;99-102.
29. Guard S., Watson S.P. Tachykinin receptor types: classification and membrane signalling mechanisms. Neurochem. Int. 18:1991;149-165.
30. Haverstick D.M., Rubenstein A., Bannon M.J. Striatal tachykinin gene expression regulated by interaction of D-1 and D-2 dopamine receptors. J. Pharmacol. Exp. Ther. 248:1989;858-862.
31. Herkenham M. Mismatches between neurotransmitter and receptor localizations in brain: observations and implications. Neuroscience. 23:1987;1-38.
32. Hershey A.D., Krause J.E. Molecular characterization of a functional cDNA encoding the rat substance P receptor. Science. 247:1990;958-962.
33. 1 receptor antagonists. Eur. J. Pharmacol. 341:1998;235-241.
34. Hua X.Y., Saria A., Gamse R., Theodorsson N.E., Brodin E., Lundberg J.M. Capsaicin induced release of multiple tachykinins (substance P, neurokinin A and eledoisin-like material) from guinea-pig spinal cord and ureter. Neuroscience. 19:1986;313-319.
35. Humpel C., Knaus G.A., Auer B., Knaus H.G., Haring C., Theodorsson E., Saria A. Effects of haloperidol and clozapine on preprotachykinin-A messenger RNA, tachykinin tissue levels, release and neurokinin-1 receptors in the striato-nigral system. Synapse. 6:1990;1-9.
36. Iyengar S., Hipskind P.A., Gehlert D.R., Schober D., Lobb K.L., Nixon J.A., Helton D.R., Kallman M.J., Boucher S., Couture R., Li D.L., Simmons R.M. LY303870, a centrally active neurokinin-1 antagonist with a long duration of action. J. Pharmacol. Exp. Ther. 280:1997;774-785.
37. Jacoby E., Boudon A., Kucharczyk N., Michel A., Fauchere J.L. A structural rationale for the design of water soluble peptide-derived neurokinin-1 antagonists. J. Recept. Signal Transduction Res. 17:1997;855-873.
38. Jensen C.J., Gerard N.P., Schwartz T.W., Gether U. The species selectivity of chemically distinct tachykinin nonpeptide antagonists is dependent on common divergent residues of the rat and human neurokinin-1 receptors. Mol. Pharmacol. 45:1994;294-299.
39. Kramer M.S., Cutler N., Feighner J., Shrivastava R., Carman J., Sramek J.J., Reines S.A., Liu G., Snavely D., Wyatt K.E., Hale J.J., Mills S.G., MacCoss M., Swain C.J., Harrison T., Hill R.G., Hefti F., Scolnick E.M., Cascieri M.A., Chicchi G.G., Sadowski S., Williams A.R., Hewson L., Smith D., Rupniak N.M. Distinct mechanism for antidepressant activity by blockade of central substance P receptors. Science. 281:1998;1640-1645. see comments.
40. Krase W., Koch M., Schnitzler H. Substance P is involved in the sensitization of the acoustic startle response by footshocks in rats. Behav. Brain Res. 63:1994;81-88.
41. 125I -MePhe7]neurokinin B, and is responsive to tachykinin peptide agonists Proc. Natl. Acad. Sci. USA. 94:1997;310-315.
42. 1 receptor antagonist to prevent delayed emesis after cisplatin. J. Natl. Cancer Inst. 89:1997;817-818. letter.
43. Kwatra M.M., Schwinn D.A., Schreurs J., Blank J.L., Kim C.M., Benovic J.L., Krause J.E., Caron M.G., Lefkowitz R.J. The substance P receptor, which couples to Gq/11, is a substrate of beta-adrenergic receptor kinase 1 and 2. J. Biol. Chem. 268:1993;9161-9164.
44. Laufer R., Gilon C., Chorev M., Selinger Z. Characterization of a neurokinin B receptor site in rat brain using a highly selective radioligand. J. Biol. Chem. 261:1986;10257-10263.
45. Lavielle S., Brunissen A., Carruette A., Garret C., Chassaing G. Highly potent substance P antagonists substituted with beta-phenyl-or beta-benzyl-proline at position 10. Eur. J. Pharmacol. 258:1994;273-276.
46. Lee C.M., Campbell N.J., Williams B.J., Iversen L.L. Multiple tachykinin binding sites in peripheral tissues and in brain. Eur. J. Pharmacol. 130:1986;209-217.
47. Lieberman D.N., Mody I. Substance P enhances NMDA channel function in hippocampal dentate gyrus granule cells. J. Neurophysiol. 80:1998;113-119.
48. Liminga U., Gunne L.M. Intranigral stimulation of oral movements by [pro(9)] substance-P, a neurokinin-1 receptor agonist, is enhanced in chronically neuroleptic-treated rats. Behav. Brain Res. 57:1993;93-99.
49. Longmore J., Hill R.G., Hargreaves R.J. Neurokinin-receptor antagonists: pharmacological tools and therapeutic drugs. Can. J. Physiol. Pharmacol. 75:1997;612-621.
50. Lundberg J.M., Saria A. Polypeptide-containing neurons in airway smooth muscle. Annu. Rev. Physiol. 49:1987;557-572.
51. Lundberg J.M., Saria A., Brodin E., Rosell S., Folkers K. A substance P antagonist inhibits vagally induced increase in vascular permeability and bronchial smooth muscle contraction in the guinea pig. Proc. Natl. Acad. Sci. USA. 80:1983;1120-1124.
52. Lundberg J.M., Saria A., Rosell S., Folkers K. A substance P antagonist inhibits heat-induced oedema in the rat skin. Acta Physiol. Scand. 120:1984;145-146.
53. Macdonald S.G., Boyd N.D. Regulation of substance P receptor affinity by guanine nucleotide-binding proteins. J. Neurochem. 53:1989;264-272.
54. Macdonald S.G., Dumas J.J., Boyd N.D. Chemical cross-linking of the substance P (NK-1) receptor to the alpha subunits of the G proteins Gq and G11. Biochemistry. 35:1996;2909-2916.
55. Maggi C.A. Tachykinins as peripheral modulators of primary afferent nerves and visceral sensitivity. Pharmacol. Res. 36:1997;153-169.
56. 1 receptor. Trends Pharmacol. Sci. 18:1997;351-355.
57. Maggi C.A., Giuliani S., Santicioli P., Regoli D., Meli A. Peripheral effects of neurokinins: functional evidence for the existence of multiple receptors. J. Auton. Pharmacol. 7:1987;11-32.
58. 2 tachykinin receptor subtypes. Eur. J. Pharmacol. 199:1991;127-129.
59. Maggi C.A., Patacchini R., Rovero P., Giachetti A. Tachykinin receptors and tachykinin receptor antagonists. J. Auton. Pharmacol. 13:1993;23-93.
60. 1 receptor antagonists, RP 67580 and SR 140333, on electrically-evoked substance P release from rat spinal cord. Br. J. Pharmacol. 113:1994;635-641.
61. Maldonado R., Girdlestone D., Roques B.P. RP 67580, a selective antagonist of neurokinin-1 receptors, modifies some of the naloxone-precipitated morphine withdrawal signs in rats. Neurosci. Lett. 156:1993;135-140.
62. Marksteiner J., Saria A., Miller C.H., Krause J.E. Differential increases of neurokinin B- and enkephalin-like immunoreactivities and their mRNAs after chronic haloperidol treatment in the rat. Neurosci. Lett. 148:1992;55-59.
63. Marksteiner J., Saria A., Miller C.H., Krause J.E. Increased synthesis of neurokinin B and enkephalin after chronic haloperidol treatment. Regul. Pept. 46:1993;349-351.
64. 1 tachykinin receptor. Med. Res. Rev. 16:1996;297-317.
65. McLean S., Ganong A., Seymour P.A., Snider R.M., Desai M.C., Rosen T., Bryce D.K., Longo K.P., Reynolds L.S., Robinson G. Pharmacology of CP-99,994; a nonpeptide antagonist of the tachykinin neurokinin-1 receptor. J. Pharmacol. Exp. Ther. 267:1993;472-479.
66. Minabe Y., Emori K., Toor A., Stutzmann G.E., Ashby J.-C.R. The effect of the acute and chronic administration of CP 96,345, a selective neurokinin1 receptor antagonist, on midbrain dopamine neurons in the rat: a single unit, extracellular recording study. Synapse. 22:1996;35-45.
67. Mitsuhashi M., Ohashi Y., Shichijo S., Christian C., Sudduth K.J., Harrowe G., Payan D.G. Multiple intracellular signaling pathways of the neuropeptide substance P receptor. J. Neurosci. Res. 32:1992;437-443.
68. Mochizuki O.N., Nakajima Y., Nakanishi S., Ito S. Characterization of the substance P receptor-mediated calcium influx in cDNA transfected Chinese hamster ovary cells. A possible role of inositol 1,4,5-trisphosphate in calcium influx. J. Biol. Chem. 269:1994;9651-9658.
69. Nakajima Y., Tsuchida K., Negishi M., Ito S., Nakanishi S. Direct linkage of three tachykinin receptors to stimulation of both phosphatidylinositol hydrolysis and cyclic AMP cascades in transfected Chinese hamster ovary cells. J. Biol. Chem. 267:1992;2437-2442.
70. Navari R.M., Reinhardt R.R., Gralla R.J., Kris M.G., Hesketh P.J., Khojasteh A., Kindler H., Grote T.H., Pendergrass K., Grunberg S.M., Carides A.D., Gertz B.J. Reduction of cisplatin-induced emesis by a selective neurokinin-1-receptor antagonist. L-754,030 antiemetic trials group. New Engl. J. Med. 340:1999;190-195.
71. Otsuka M., Yoshioka K. Neurotransmitter functions of mammalian tachykinins. Physiol. Rev. 73:1993;229-308.
72. 1 receptor antagonist LY303870 inhibits neurogenic dural inflammation in guinea pigs. Life Sci. 60:1997;1553-1561.
73. 3 receptor agonists in the guinea-pig. Br. J. Pharmacol. 116:1995;2496-2502.
74. 1 receptors mediate the inhibitory effect of tachykinins on angiotensin-induced drinking in rats. Peptides. 19:1998;149-155.
75. Pradier L., Habert O.E., Emile L., Le G.J., Loquet I., Bock M.D., Clot J., Mercken L., Fardin V., Garret C. Molecular determinants of the species selectivity of neurokinin type 1 receptor antagonists. Mol. Pharmacol. 47:1995;314-321.
76. Quartara L., Maggi C.A. The tachykinin NK1 receptor: Part I. ligands and mechanisms of cellular activation. Neuropeptides. 31:1997;537-563.
77. Quartara L., Maggi C.A. The tachykinin NK1 receptor: Part II. Distribution and pathophysiological roles. Neuropeptides. 32:1998;1-49.
78. 1 receptor antagonists LY303870 and LY306740 block the responses of spinal dorsal horn neurons to substance P and to peripheral noxious stimuli. Neuroscience. 83:1998;1251-1260.
79. Regoli D., Nantel F. Pharmacology of neurokinin receptors. Biopolymers. 31:1991;777-783.
80. Regoli D., Boudon A., Fauchere J.L. Receptors and antagonists for substance P and related peptides. Pharmacol. Rev. 46:1994;551-599.
81. Regoli D., Drapeau G., Dion S., Couture R. New selective agonists for neurokinin receptors: pharmacological tools for receptor characterization. Trends Pharmacol. Sci. 9:1988;290-295.
82. Regoli D., Drapeau G., Dion S., D'Orleans J.P. Pharmacological receptors for substance P and neurokinins. Life Sci. 40:1987;109-117.
83. Regoli D., Drapeau G., Dion S., D'Orleans J.P. Receptors for substance P and related neurokinins. Pharmacology. 38:1989;1-15.
84. 1 tachykinin receptor antagonist, CP 99,994, in antagonizing the acute and delayed emesis induced by cisplatin in the ferret. Br. J. Pharmacol. 119:1996;931-936.
85. 1 receptor antagonists. Eur. J. Pharmacol. 326:1997;201-209.
86. Sachais B.S., Krause J.E. Both extracellular and transmembrane residues contribute to the species selectivity of the neurokinin-1 receptor antagonist WIN 51708. Mol. Pharmacol. 46:1994;122-128.
87. Sachais B.S., Snider R.M., Lowe J.A., Krause J.E. Molecular basis for the species selectivity of the substance P antagonist CP-96,345. J. Biol. Chem. 268:1993;2319-2323.
88. 3 ligands) in the rat brain. Peptides. 9:1988;227-241.
89. Saria A. Substance P in sensory nerve fibres contributes to the development of oedema in the rat hind paw after thermal injury. Br. J. Pharmacol. 82:1984;217-222.
90. Saria A., Gamse R., Petermann J., Fischer J.A., Theodorsson N.E., Lundberg J.M. Simultaneous release of several tachykinins and calcitonin gene-related peptide from rat spinal cord slices. Neurosci. Lett. 63:1986;310-314.
91. 1) antagonists CP-96,345 and RP 67580. Regul. Pept. 46:1993;346-348.
92. 1 (long) receptors expressed in Chinese hamster ovary cells. Neurosci. Lett. 152:1993;9-12.
93. Shaikh M.B., Steinberg A., Siegel A. Evidence that substance P is utilized in medial amygdaloid facilitation of defensive rage behavior in the cat. Brain Res. 625:1993;283-294.
94. Shigemoto R., Nakaya Y., Nomura S., Ogawa-Meguro R., Ohishi H., Kaneko T., Nakanishi S., Mizuno N. Immunocytochemical localization of rat substance P receptor in the striatum. Neurosci. Lett. 153:1993;157-160.
95. 1 receptor antagonist PD 154075 blocks cisplatin-induced delayed emesis in the ferret. Eur. J. Pharmacol. 321:1997;209-216.
96. Sivam S.P., Krause J.E. Tachykinin systems in the spinal cord and basal ganglia: influence of neonatal capsaicin treatment or dopaminergic intervention on levels of peptides, substance P-encoding mRNAs, and substance P receptor mRNA. J. Neurochem. 59:1992;2278-2284.
97. Sivam S.P., Krause J.E., Takeuchi K., Li S., McGinty J.F., Hong J.S. Lithium increases rat striatal beta- and gamma-preprotachykinin messenger RNAs. J. Pharmacol. Exp. Ther. 248:1989;1297-1301.
98. 1) receptor. Science. 251:1991;435-437.
99. 1 tachykinin receptor agonist. Brain Res. 700:1995;115-120.
100. Sundelin J.B., Provvedini D.M., Wahlestedt C.R., Laurell H., Pohl J.S., Peterson P.A. Molecular cloning of the murine substance K and substance P receptor genes. Eur. J. Biochem. 203:1992;625-631.
101. Takeda Y., Blount P., Sachais B.S., Hershey A.D., Raddatz R., Krause J.E. Ligand binding kinetics of substance P and neurokinin A receptors stably expressed in Chinese hamster ovary cells and evidence for differential stimulation of inositol 1,4,5-trisphosphate and cyclic AMP second messenger responses. J. Neurochem. 59:1992;740-745.
102. 1 receptor antagonist CP-99,994 attenuates cisplatin induced emesis in the ferret. Eur. J. Pharmacol. 250:1993;R5-R6.
103. Tattersall F.D., Rycroft W., Hill R.G., Hargreaves R.J. Enantioselective inhibition of apomorphine-induced emesis in the ferret by the neurokinin1 receptor antagonist CP-99,994. Neuropharmacology. 33:1994;259-260.
104. 1 receptor antagonists act centrally to inhibit emesis induced by the chemotherapeutic agent cisplatin in ferrets. Neuropharmacology. 35:1996;1121-1129.
105. Tavorath R., Hesketh P.J. Drug treatment of chemotherapy-induced delayed emesis. Drugs. 52:1996;639-648.
106. Teixeira R.M., Santos A.R., Ribeiro S.J., Calixto J.B., Rae G.A., De L.T. Effects of central administration of tachykinin receptor agonists and antagonists on plus-maze behavior in mice. Eur. J. Pharmacol. 311:1996;7-14.
107. 1 tachykinin receptor antagonist with good oral analgesic activity in chronic pain models. J. Med. Chem. 41:1998;3159-3173.
108. 1 receptor antagonist. Br. J. Pharmacol. 124:1998;83-92.
109. Watson J.W., Gonsalves S.F., Fossa A.A., McLean S., Seeger T., Obach S., Andrews P.L. The anti-emetic effects of CP-99,994 in the ferret and the dog: role of the NK1 receptor. Br. J. Pharmacol. 115:1995;84-94.
110. Whitty C.J., Walker P.D., Goebel D.J., Poosch M.S., Bannon M.J. Quantitation, cellular localization and regulation of neurokinin receptor gene expression within the rat substantia nigra. Neuroscience. 64:1995;419-425.
111. Whitty C.J., Paul M.A., Bannon M.J. Neurokinin receptor mRNA localization in human midbrain dopamine neurons. J. Comp. Neurol. 382:1997;394-400.
112. Yokota Y., Sasai Y., Tanaka K., Fujiwara T., Tsuchida K. Molecular characterization of a functional cDNA for rat substance P receptor. J. Biol. Chem. 264:1989;17649-17652.
113. Yu Z., Cheng G., Huang X., Li K., Cao X. Neurokinin-1 receptor antagonist SR140333: a novel type of drug to treat cerebral ischemia. NeuroReport. 8:1997;2117-2119.
114. 1) receptor antagonist (±)-CP-96,345 causes sedation and motor impairment in Swiss albino mice in the black-and-white box behavioral paradigm. Neurosci. Lett. 143:1992;169-172.
115. 1) antagonists CP-96,345 and RP 67580 in Swiss albino mice in the black-and-white box. Neurosci. Lett. 151:1993;64-66.